Edition:
United States

Concordia International Corp (CXRX.OQ)

CXRX.OQ on NASDAQ Stock Exchange Global Select Market

0.78USD
15 Dec 2017
Change (% chg)

$-0.08 (-9.57%)
Prev Close
$0.86
Open
$0.84
Day's High
$1.09
Day's Low
$0.68
Volume
1,417,320
Avg. Vol
80,072
52-wk High
$3.52
52-wk Low
$0.45

Summary

Name Age Since Current Position

Jordan Kupinsky

44 2016 Non-Executive Independent Chairman of the Board

Wayne Kreppner

41 2015 President, Chief Operating Officer

Allan Oberman

59 2016 Chief Executive Officer, Director

David Price

2017 Chief Financial Officer

Graeme Duncan

2017 President - Company's International Segment

Arijit Mookerjee

2015 Managing Director, Chief Financial Officer - Operations

Adeel Ahmad

2013 Chief Financial Officer of AMCo

Francesco Tallarico

2014 Chief Legal Officer and Secretary

Douglas Deeth

69 2013 Independent Director

Rochelle Fuhrmann

47 2015 Independent Director

Itzhak Krinsky

64 2017 Independent Director

Francis Perier

55 2017 Independent Director

Patrick Vink

54 2016 Independent Director

Biographies

Name Description

Jordan Kupinsky

Mr. Jordan M. Kupinsky, J.D., is an Non-Executive Independent Chairman of the Board of the Board of the Company. Mr. Kupinsky is the President of Justley Capital Corporation, a private investment and advisory firm. From April 2008 through September 2016 Mr. Kupinsky was a partner with JJR Private Capital. For part of that time (January 2011 through July 2014), Mr. Kupinsky was also Managing Director with Windsor Private Capital, a private merchant banking firm. Mr. Kupinsky was a Vice President at Greenhill & Co., an independent global investment banking firm, listed on the NYSE, focused on mergers and acquisitions and financial restructuring from March 2006 to May 2008. Prior to joining Greenhill, Mr. Kupinsky held the positions of Vice President of Corporate Development and General Counsel at Minacs Worldwide Inc., a publicly traded company on the TSX from July 2002 to February 2005. Mr. Kupinsky began his career practicing corporate and securities law at Torys LLP in Toronto (from 1997 to 1999) and was also an investment banking associate at Houlihan Lokey Howard & Zukin from 1999 to 2002. He holds a joint MBA and JD degree from the Schulich School of Business and Osgoode Hall Law School at York University. Mr. Kupinsky is currently a director of Atlas Financial Holdings Inc. Mr. Kupinsky has also served as a director of Perk Inc. and Xceed Mortgage Corporation.

Wayne Kreppner

Mr. Wayne Kreppner has been promoted as President, Chief Operating Officer of the Company, q was Vice-President of Product Development at Trimel Pharmaceuticals from October 2008 to November 2013. Various senior roles in regulatory affairs and operations with Biovail Corporation.

Allan Oberman

Mr. Allan Oberman is Chief Executive Officer, Director of the Company. Mr. Oberman brings more than 15 years of international pharmaceutical industry experience to Concordia including his recent role as Chief Executive Officer of specialty pharmaceutical company Sagent Pharmaceuticals, Inc. Sagent was sold to Nichi-Iko Pharmaceutical Co. Ltd., Japan’s largest generic drug manufacturer, in a transaction that closed on August 29, 2016. Prior to Sagent, from November 2012 to December 2014, Mr. Oberman served as President and CEO of Teva Americas Generics, a region which included the U.S., Canada and Latin America. He joined Teva in 2000 and served as President of Teva EMIA (Eastern Europe, Middle East, Israel and Africa), where he led a diverse group of countries in achieving consistent sales growth. Mr. Oberman also served as the Chief Operating Officer of Teva International, and President and CEO of Teva Canada, formerly known as Novopharm Limited.

David Price

Mr. David J. Price is a Chief Financial Officer of the Company. Mr. Price will begin his role onMay 15, 2017, at which time he will report to Chief Executive Officer (CEO)Allan Oberman. In the interim, the Company's financial responsibilities will be overseen and managed byAdeel Ahmad, CFO of the International segment of Concordia, andBryan Jacobs, corporate controller of Concordia. The timing of this announcement is unrelated to Concordia's first quarter 2017 financial results or earnings process. The Company intends to conduct its first quarter earnings call onMay 10, 2017in the ordinary course. Mr. Price brings over 25 years of experience in the healthcare, investment banking and accounting industries. Most recently, he served as CFO of Bioventus Inc., a private equity-backed global provider of medical devices in the orthobiologics field. In this role, Mr. Price oversaw global finance and information technology (IT) functions, refinanced the company's debt to implement a successful M&A strategy, and played a key role in building and overseeing optimization and efficiency practices for Bioventus around the globe. Prior to his role at Bioventus, Mr. Price held CFO positions at two other companies. As the CFO, chief operating officer and corporate treasurer at EDGAR Online Inc. - a financial data, technology and business process outsourcing (BPO) company - Mr. Price was responsible for all financial strategy and reporting, investor relations, corporate development, human resources and BPO operations in the US,EuropeandIndia. Prior to EDGAR Online, Mr. Price was the CFO and corporate treasurer for Cornerstone Therapeutics, Inc., a publicly traded specialty pharmaceutical company.

Graeme Duncan

Mr. Graeme Duncan has been appointed as President - Company's International Segment of the Company effective January 1, 2017. He was Global Marketing Director and Vice President, Concordia International from September 2016 to January 2017. Vice President, UK and Ireland, Global Marketing Director, Concordia International from October 2015 to October September 2016. UK General Manager and Global Marketing Director, AMCo from October 2014 to October 2015. Director of Global Strategy, Healthcare at Home Ltd. from December 2012 to December 2013. Director of Pharmaceuticals, Healthcare at Home Ltd. from January 2011 to December 2012.

Arijit Mookerjee

Mr. Arijit Mookerjee is the Managing Director and Chief Financial Officer - Operations of the Company. Head of Finance of the South Asia & Middle East Division of SMEC, an Australian engineering consultancy multinational, from May 2013 to May 2015, prior to which Mr. Mookerjee was an audit director with PricewaterhouseCoopers LLP in Barbados.

Adeel Ahmad

Mr. Adeel Ahmad is Chief Financial Officer of AMCo., a subsidiary of the Company. He was Vice President, Finance and Controller of the Corporation from December 2013 to February 2016, Chief Financial Officer, Ingram Micro Mobility from February 2012 to May 2013, Director of Finance, Asia, Nortel August 2010 to January 2012.

Francesco Tallarico

Mr. Francesco Tallarico is Chief Legal Officer and Secretary of the Company. He was Vice President, Legal Affairs of the Corporation from November 2014 to November 2015. Associate, Fasken Martineau DuMoulin LLP, from May 2010 to November 2014.

Douglas Deeth

Mr. Douglas N. Deeth is Independent Director of Concordia Healthcare Corp. Mr. Deeth is a partner with the law firm of Deeth Williams Wall LLP. He is the former President of the Intellectual Property Law section of the Canadian Bar Association, the current President of the International Federation of Intellectual Property Attorneys (FICPI) and has over 35 years of experience working with the pharmaceutical industry. Throughout most of his career Mr. Deeth has been extensively involved in product and technology acquisition and licensing agreements in the pharmaceutical field. He has been recognized in several international reviews as one of Canada’s leading intellectual property lawyers. He was a director of Trimel Pharmaceuticals Inc., and is on the board of directors of IM Biotechnologies Inc. Mr. Deeth was admitted to the Bar of Ontario in 1976. He has a B.A.Sc. in Chemical Engineering from the University of Waterloo (1970) and an LL.B. from the University of Toronto (1974), and has taught, written and spoken extensively on intellectual property law. He has lectured at McMaster University, the University of Toronto and Osgoode Hall law schools and the McGill courses on Patent and Copyright Law.

Rochelle Fuhrmann

Ms. Rochelle Fuhrmann is an Independent Director of Concordia Healthcare Corp. Ms. Fuhrmann has over 20 years of broad financial experience and is currently the Chief Financial Officer, Life Sciences of Becton, Dickinson and Company (a diagnostics, bioscience and medical device company) and was previously the Chief Financial Officer of Amneal Pharmaceuticals LLC. Prior to joining Amneal, Ms. Fuhrmann was Senior Vice President, Finance at Warner Chilcott plc, a specialty pharmaceuticals company, prior to its acquisition by Actavis, Inc. in 2013. She spent the early part of her career in telecommunications and public accounting having held various positions at AT&T and Coopers and Lybrand LLC (now PricewaterhouseCoopers LLP). Ms. Fuhrmann earned her certified public accountant designation (inactive) in 1996 and has a B.Sc. degree in accounting from the University of Rhode Island.

Itzhak Krinsky

Prof. Itzhak Krinsky is Independent Director of the Company. Professor Krinsky retired from Teva Pharmaceutical Industries Ltd. in February 2017. He joined Teva in 2005 and served as an Executive Vice President, Corporate Business Development as well as a member of the Teva Executive Committee from 2005 to 2014. Prof. Krinsky became an active Chairman of Teva Japan; Chairman of Teva S. Korea and Head of Business Development Asia Pacific in October 2012 - a position he held until April 2016. In 2014, SCRIP, one of the most prestigious pharmaceutical media outlets, selected Prof. Krinsky as one of the 100 Global Leaders of the industry. Prior to joining Teva, he held various senior positions in investment banks in New York City including with Bankers Trust, Deutsche Bank and the Silverfern Group, Inc. (1998 to 2005). Prior to his tenure on Wall Street, Prof. Krinsky had a distinguished academic career as a Professor of Finance & Business Economics at the Michael G. DeGroote School of Business, McMaster University, Canada (1983 to 2000). Prof. Krinsky has published more than 80 articles in leading peer reviewed academic journals. Professor Krinsky holds a BA and MA in Economics from Tel Aviv University, Israel & a Ph.D. in Economics from McMaster University, Ontario Canada.

Francis Perier

Mr. Francis I. Perier is Independent Director of the Company. Mr. Perier, Jr. is a retired healthcare executive. He is the former Executive Vice President Finance and Chief Financial Officer of Forest Laboratories, Inc., a NYSE listed specialty pharmaceutical company, which was acquired by Actavis, Plc. (presently Allergan, Plc.) in July 2014. Mr. Perier served as Forest Laboratories, Inc.’s Chief Financial Officer from September 2004 until October 2014 and during his tenure had responsibilities for both finance (financial planning and reporting, treasury, tax, risk management, investor relations and external communications) and administration (human resources and legal) functions. Prior to Forest Laboratories, Inc., Mr. Perier was Vice President of Finance and Operations Planning - Americas Medicines Group at the Bristol-Myers Squibb Company, where he worked in several corporate and operational finance capacities between March 1996 and August 2004. Prior to the Bristol-Myers Squibb Company, Mr. Perier was an accounting and auditing partner with Deloitte and Touche, LLP, a leading global public accounting and professional services firm, where he worked for 14 ½ years. Mr. Perier is a Certified Public Accountant (inactive) and holds a Bachelor of Science - Accountancy from Villanova University and a Masters of Business Administration - Management from New York University Stern School of Business.

Patrick Vink

Dr. Patrick Vink is Independent Director of the Company. Dr. Vink is an advisor to life science companies. Mr. Vink is currently the Chairman of the board of directors of Acacia Pharma, the Chairman of NMD Pharma, a director of Spero Therapeutics, a director of Santhera Pharmaceuticals Holding AG, and a director of Arch Biopartners Inc. Previously, Mr. Vink was the Chairman of the board of directors of Micreos BV and Piqur AG. Mr. Vink served as Chief Operating Officer of Cubist Pharmaceuticals Inc. until its acquisition by Merck and Co. in 2015. Previously, Mr. Vink served as Senior Vice-President, Head of Global Institutional and Biologics Business at Mylan Inc., which he joined in 2008 establishing the company’s global hospital operations in Switzerland. Mr. Vink has held several leadership positions across the pharmaceutical industry, including head of global business franchise biopharmaceuticals for Novartis Sandoz; vice president for international business for Biogen Inc.; and head of worldwide marketing, cardiovascular and thrombosis for Sanofi-Synthelabo. Mr. Vink served as a member of the executive committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015. Mr. Vink graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his MBA in 1991 at the University of Rochester.

Basic Compensation